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Key points  9 • Liver biopsies obtained within 30 days of onset from 212 patients with drug-induced liver 10 
injury were analyzed for the associations of gender and a proxy of female menopausal 11 
status with histologic features in the acute injury phase. 12 • Biopsies of the 58 women < 50 years of age were associated with more severe interface 13 
hepatitis and less iron-stained hepatocytes vs. those of the 87 men and 67 women ≥ 50 14 
years.  15 • Compared to those of men, biopsies of women showed significantly greater plasma cell 16 
infiltration, hepatocyte apoptosis, hepatocyte rosettes, and lobular disarray. 17 • Biopsies from men showed greater histological cholestasis.  18 
Abstract  19 
[Background and aim] Gender and menopause may contribute to type and severity of drug-20 
induced liver injury (DILI) by influencing host responses to injury. The aim of this study was to 21 
assess the associations of gender and female age 50 [a proxy of menopause] with histologic 22 
features of liver injury in 212 adults enrolled in the Drug-Induced Liver Injury Network (DILIN) 23 
registry. [Methods] All participants had a causality score of at least ‘probable’, a liver biopsy 24 
within 30 days of DILI onset, and no prior chronic liver disease. Biochemical and histologic injury 25 
types were classified as hepatocellular or cholestatic/mixed injury. The cohort was divided into 26 
three gender/age categories: men (41.0%), women < 50 years (27.4%), and women ≥ 50 years 27 
of age (31.6%). Interaction of gender and age category (≥50 or not) was assessed. [Results] 28 
Hepatocellular injury was more prevalent in women < 50 years vs. others (p=0.002). After 29 
adjusting for biochemical injury types, black race and possible aging effects, more severe 30 
interface hepatitis was noted in biopsies of women < 50 years compared to those of men and 31 
women ≥ 50 years (p=0.009 and p=0.055, respectively). Compared to those of men, biopsies of 32 
women showed greater plasma cell infiltration, hepatocyte apoptosis, hepatocyte rosettes, and 33 
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lobular disarray but less iron-positive hepatocytes and histological cholestasis (p<0.05).  These 1 
associations persisted after excluding cases of amoxicillin/clavulanic acid, anabolic steroids or 2 
nitrofurantoin DILI which showed gender-specific distributions. [Conclusion] Gender and a 3 
proxy of menopause were associated with various features of inflammation and injury in DILI.  4 
Key words: drug-induced liver injury, gender difference, menopause, liver histology, 5 
hepatotoxicity. 6 
 7 
INTRODUCTION  8 
Significant heterogeneity exists in clinical phenotypes of drug-induced liver injury (DILI). Initial 9 
biochemical presentations, autoimmune features, liver histology, and clinical outcomes vary 10 
substantially among individuals who develop DILI, even when caused by the same agent.[1-4] 11 
Such heterogeneity suggests that how individuals respond to drug toxicity, cellular stress and 12 
tissue injury may contribute to the variable clinical phenotypes of DILI.   13 
Gender and sex hormones influence drug metabolism and transport.[5, 6] They also modulate 14 
host responses to injury; sexual dimorphism in cellular stress response, cell death, immune 15 
response, inflammation and tissue repair has been demonstrated in various systems. In 16 
particular, sexual dimorphism in the immune response has been well documented in humans as 17 
well as experimental models.[7]  Several recent experimental studies demonstrated sex 18 
differences in host responses to injury. An immune-mediated DILI model showed sex 19 
differences in immune response and inflammation: more severe hepatitis, more antibody 20 
production, and a higher level of pro-inflammatory hepatic cytokines in females vs. male 21 
mice.[8] In the halothane-induced liver injury mouse model, estrogens reduce injury while 22 
progesterone exacerbates injury.[9, 10] In an immune-mediated nephritis model more apoptosis 23 
occurred in females vs. more necrosis in males, and the administration of estrogen to male mice 24 
induced apoptosis and inhibited necrosis.[11] Taken together, these findings suggest that 25 
gender and sex hormones may modulate host responses to liver injury insults and contribute to 26 
diverse clinical manifestation and severity of human DILI.  27 
We hypothesized that gender and sex hormones modulate cellular stress responses, cell death, 28 
immune responses, and inflammation in drug toxicity and may influence clinical and histologic 29 
DILI manifestations in humans. We aimed to investigate the associations of gender and 30 
women’s age (with ≥ 50 years as a surrogate for menopause) with histologic features in acute 31 
phase of DILI, for the purpose of further refining the above-mentioned hypothesis. Our thorough 32 
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descriptive analyses using different modeling approaches identified several histologic features 1 
associated with gender (and women’s age < 50) across initial biochemical presentations even 2 
after excluding gender-specific causal agents. The findings support the above-mentioned 3 
hypothesis and also pose important clinical and pathophysiological questions relevant to 4 
gender-differences in DILI phenotypes, which should be further investigated across different 5 
disciplines.     6 
METHODS 7 
Study design and data source 8 
This is a hypothesis-driven, cross sectional analysis designed to investigate the associations of 9 
gender and female menopausal status with various histologic features in patients with DILI. 10 
Data from the U.S. Drug-Induced Liver Injury Network (DILIN) were utilized in our analysis. The 11 
study design and data collection in the prospective DILIN database study have been previously 12 
described.[12] Briefly, the consortium enrolls consecutive adult and pediatric patients with 13 
suspected DILI. Detailed clinical information, including laboratory data, medications, medical & 14 
social history, and symptoms and signs at DILI onset, was collected at the time of study 15 
enrollment. DILI onset was defined per protocol as date of initial presentation with elevated liver 16 
enzymes that met any of the study criteria.[12] Causality assessment was performed by the 17 
DILIN causality committee in a consensus manner using the DILIN causality score after 6 18 
months follow-up. For subjects who showed evidence of persisting DILI [13] , additional follow-19 
up evaluations were performed at 12 months and 24 months. [12] Liver biopsy was not required 20 
for study enrollment. When liver biopsy was performed for clinical indications, biopsy slides 21 
were obtained from the clinical study centers. The clinical decision on whether to perform a liver 22 
biopsy was solely made by the attending physician who often differed from the DILIN 23 
investigator.  The DILIN studies were approved by the Institutional Review Board (IRB) at each 24 
participating center (listed in Supplemental Methods). Informed consent was obtained from each 25 
of the participants prior to the study enrollment. 26 
Study population 27 
Of 1386 enrolled patients between September 2004 and May 2014, 212 (15%) patients who met 28 
the following criteria were analyzed: 1) Age > 18 years 2) an adequate, evaluable liver biopsy 29 
that had been performed within 30 days of DILI onset, 3) a DILIN causality score of ‘probable’ or 30 
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higher [14], 4) no prior diagnosis of other chronic liver diseases. The time window for this study 1 
was set to focus on histologic features in acute phase.   2 
Study variables 3 
Predictors:
15
 The primary predictor variable tested in this study was the gender/female 4 
menopause classification. As reproductive information was not collected as a part of the DILIN 5 
study, age 50 years old, the average age of female menopause in the US, was used as a 6 
surrogate.[ ] Prior to our main analyses, we performed background analyses to assess an 7 
interaction between gender and age 50 in each histologic feature to better characterize aging 8 
effect vs. menopausal effect as detailed in Supplemental Statistical Method. Based on the 9 
background analyses, the study population was classified into 3 categories (hereafter called the 10 
gender/age categories), men, women younger than 50 years (surrogate for premenopausal), 11 
and women 50 years old or older (surrogate for postmenopausal) in our main analyses. Gender 12 
(men vs. all women) was also assessed as the secondary predictor.  13 
Outcomes
16
: Liver biopsy slides stained with hematoxylin-eosin and Masson trichrome stain were 14 
obtained from the clinical study centers and were reviewed and scored in a blinded, 15 
standardized manner by a single experienced hepatopathologist [DEK].[ ] Histologic features, 16 
including interface hepatitis, plasma cell infiltration, cholestatic degree, hepatocellular 17 
cholestasis, canalicular cholestasis, hepatocyte rosettes, lobular disarray, iron stain-18 
hepatocellular iron, and apoptosis, were analyzed as primary study outcomes in this study.  19 
Histologic injury types were classified into the following two categories based on the histologic 20 
injury patterns: cholestatic/mixed injury (i.e., acute cholestatic, chronic cholestatic, and 21 
combined hepatitic/cholestatic) and hepatocellular (i.e., others).[16] 22 
Others: 
17
Initial biochemical injury types, hepatocellular [HC] injury and cholestatic/mixed 23 
[CS/MIX] injury, were determined based on the R ratio at the time of DILI onset or the closest to 24 
the onset when the laboratory data were not available at the onset, calculating the ratio of 25 
serum alanine aminotransferase (ALT)/upper limit normal (ULN) to serum alkaline phosphatase 26 
(ALP)/ULN:   >= 5 (HC) vs. < 5 (CS/MIX).[ ]  R-values were calculated using institutional 27 
reference ranges of serum ALT and ALP at the time of case enrollment. Information on 28 
demography, laboratory data at the study enrollment, and suspected drugs was also obtained 29 
for our analyses.  30 
 31 
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Statistical analyses  1 
Descriptive data are reported as mean ± standard deviation or median with interquartile range 2 
for continuous variables and as a percentage for categorical variables. To assess selection bias 3 
due to the lack of liver biopsy within 30 days of DILI onset, clinical characteristics of the study 4 
population were compared between those included in the analysis versus those not included in 5 
the analysis (i.e., age > 18 years, a DILIN causality score of ‘probable’ or higher, and no prior 6 
diagnosis of other chronic liver diseases, but no biopsies within 30 days of DILI onset). 7 
Clinical characteristics of the study population were compared among the gender/age 8 
categories by using Kruskal-Wallis test for continuous and ordinal variables and chi-square test 9 
for categorical variables. Histological features of the study population were similarly compared 10 
among the gender/age categories with stratification on different biochemical injury types.   11 
For modeling the histologic features, univariate analysis was performed first to select potential 12 
clinical covariates for adjustment in the multivariate models. To determine a proper age variable 13 
to be included in a model, background analyses were performed as described in Supplemental 14 
Statistical Methods. Depending on the histologic outcomes (binary vs. ordinal), logistic 15 
regression models or ordinal logistic regression models were used. For the ordinal logistic 16 
regression, proportional odds models or cumulative logistic regression models were selected, 17 
depending on whether or not the proportional odds assumption was met for a specific histologic 18 
outcome. Adjusted odds ratio or cumulative odds ratio with 95% confidence interval (CI) and p 19 
value were reported. The fit of the models was assessed with Hosmer-Lemeshow goodness-of-20 
fit test for binary and ordinary outcomes.[18]  21 
Statistical analyses were performed using SAS version 9.4. (SAS Institute, Cary, NC). All P 22 
values presented are 2-sided, and the differences were considered statistically significant when 23 
the P<0.05. For detecting interactions in the background analyses, we used p<0.1 due to the 24 
small sample size. Because of the descriptive nature of this analysis, P values have not been 25 
adjusted for multiple comparisons.  26 
 27 
RESULTS 28 
Clinical characteristics 29 
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A total of 212 adults with DILI were included in the analysis. Clinical characteristics of the study 1 
population at enrollment are summarized in Table 1. Women of age <50 years, women of age 2 
≥50 years, and men comprised 27.4%, 31.6%, and 41.0% of the study population, respectively. 3 
Mean [+ SD] age of the total study population was 50 ±16 years old. Seventy-seven percent 4 
were white, 14.6% black, and 10% Hispanic. Fifty percent of the cases presented as HC injury 5 
at DILI onset. Age, the biochemical presentation at DILI onset, serum ALT, serum AST, serum 6 
ALP, and positive ANA were significantly different among the gender/age categories (Table 1). 7 
Hepatocellular injury was noted in 70.7% of women of <50 years compared to 43.3% of women 8 
of >=50 years and 41.4% of men. Serum ALT and AST were the highest in women aged <50 9 
years, while serum ALP was the highest in women aged ≥50 years. Men had a lower frequency 10 
of positive ANA (14.5%) compared to women (>30% in both groups) at the study enrollment. 11 
Black, other race, and Hispanic were more prevalent among women of age <50 years although 12 
there were no statistical significances. 13 
The clinical characteristics of the study population were then compared with the patients 14 
excluded from this analysis due to the lack of liver biopsy within 30 days of the DILI onset. The 15 
clinical characteristics of the study population (N=212) vs. the population not included in this 16 
analysis (N=792) are summarized in Supplementary Table 2. Briefly, clinical severity score, 17 
serum ALP, and total bilirubin at DILI onset were higher in the study population. The age, the 18 
gender/age categories, self-reported race/ethnicity, biochemical injury type at DILI onset, and 19 
positive ANA did not show statistical differences between the populations. Biochemical injury 20 
type, clinical severity score, and positive ANA were further analyzed, classifying by the 21 
age/gender categories in each population (Supplementary Table 3). No statistically significant 22 
interactions (the populations x the age/gender categories) were noted.  23 
Causal agents implicated in the study population are provided in Supplementary Table 1a and 24 
1b. Among agents implicated in ≥4 cases (Table 1), Herbs-Dietary Supplement (HDS) was most 25 
prevalent (25%), followed by amoxicillin/clavulanic acid (12.2%). Eleven cases of the HDS-26 
related DILI were caused by anabolic steroids, all of whom were males. 27 
Univariate associations of the histologic features with the gender/age categories  28 
The previous analysis demonstrated the histologic features significantly differ depending on the 29 
initial biochemical presentations: hepatocellular vs. cholestatic/mixed injury.[16] Therefore, the 30 
univariate associations were assessed not only in the total study population but also within the 31 
groups of hepatocellular injury and cholestatic/mixed injury separately (Table 2). Several 32 
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variables were significantly associated with the gender/age categories. It is notable that, across 1 
the injury types, interface hepatitis, noticeable increase in plasma cells, apoptosis, hepatocyte 2 
rosettes, and lobular disarray showed a female-dominant pattern while cholestasis and 3 
hepatocyte iron-positivity by Perls’ staining showed a male-dominant pattern. These histologic 4 
features were considered in the multivariable analyses. 5 
Adjusted associations of the histologic features with the gender/age categories 6 
In our background analyses, a potential effect of advancing age was only evident in interface 7 
hepatitis at age of 70 in both men and women. The age category (<50 vs. ≥50) did not show 8 
significant associations with any histologic features in men. There was an interaction of gender 9 
and the age category in the histologic features of interface hepatitis (P=0.05) and apoptosis 10 
(p=0.06).  11 
The adjusted associations of histologic features with 1) the gender/age categories (Model 1) 12 
and 2) gender (Model 2) are presented in Table 3. All the models were adjusted for biochemical 13 
injury types, black race, and, for interface hepatitis only, the age category (<70 vs. ≥70). The 14 
goodness of fit tests indicated an adequate fit (p-values of 0.27 to 0.99).  More severe interface 15 
hepatitis and less hepatocyte iron stains were noted in biopsies of women < 50 years compared 16 
to those of men and women ≥ 50 years (p=0.009 and p=0.055 for interface hepatitis and 17 
p<0.001 and p=0.046 for hepatocyte iron stains, respectively). Compared to those of men, 18 
biopsies of women were associated with more plasma cell infiltration, more apoptosis, more 19 
hepatocyte rosettes, more lobular disarray, and less iron-stained hepatocytes and less 20 
cholestasis (p<0.05).   21 
Amoxicillin/clavulanic acid, anabolic steroids and nitrofurantoin, which showed gender-specific 22 
distributions in this study population, have been associated with signature injury patterns. 23 
Therefore, we assessed the associations between the histologic features and the gender/age 24 
categories (or gender) after excluding these agents. These associations remained similar even 25 
after excluding cases due to anabolic steroids, nitrofurantoin, or amoxicillin/clavulanic acid (data 26 
are not shown).  27 
The associations of histologic features with the gender/age categories and gender were also 28 
assessed using the same modeling strategy but adjusting for the histologic injury classification, 29 
which showed similar results, except for hepatocellular/canalicular cholestasis; the odds ratios 30 
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of men vs. women were decreased for hepatocellular/canalicular cholestasis (data are not 1 
shown).     2 
DISCUSSION  3 
This hypothesis-refining analysis revealed intriguing findings pertaining to gender-specific 4 
phenotypes of DILI.  Women <50 years of age were more likely to show severe interface 5 
hepatitis and less hepatocyte iron staining compared to men and women >50 years. The 6 
comparable risk reduction in women >50 years and men vs. women <50 years of age implies 7 
the involvement of female sex hormones as opposed to innate sex difference in the pathology 8 
involved in these features. For this interpretation, we considered a possible indication bias; 9 
young women with positive ANA and high serum ALT and AST might have undergone liver 10 
biopsies more often than others to rule out autoimmune hepatitis. However, we found no 11 
evidence of bias regarding frequencies of liver biopsies that could explain more severe 12 
autoimmune hepatitis features in women aged < 50 vs. women aged ≥ 50 and men 13 
(Supplementary Tables 2 and 3); the study population appeared to have similar proportions of 14 
positive ANA in each age/gender category as compared to the excluded population (interaction 15 
P=0.29). Positive ANA is observed among healthy general population.[19, 20] Thus whether 16 
positive ANA is an innocent bystander, or a risk factor of developing hepatotoxicity, or a 17 
consequence of hepatotoxicity observed in a subgroup of patients is uncertain. Numbers of iron-18 
positive hepatocytes were the highest in men, intermediate in women ≥50 years, and the lowest 19 
in women <50 years of age.  Similar male dominance in hepatic iron deposition has been 20 
reported in a cohort of NAFLD.[21]  This might be explained by blood loss of menstruation, 21 
pregnancy, and breast feeding and/or estrogen’s effect on hepcidin.[22] 22 
 23 
Men had a higher likelihood of cholestatic features with a higher severity compared to women. 24 
Of note, our ‘risk of bias’ assessment showed comparable biochemical injury type within the 25 
age/gender categories between the study population and the excluded population (interaction 26 
P=0.67 in Supplemental Table 3). The consistent observation after excluding the cases caused 27 
by anabolic steroids or amoxicillin/clavulanic acid ruled out the possible explanation by male 28 
dominance observed with these agents (data not shown). Unlike the autoimmune hepatitis 29 
features, the gender difference in cholestatic features appeared to be consistent before and 30 
after the age 50 years. Our extended analysis showed that male gender (OR and 95%CI=2.0 31 
[1.1, 3.6], p=0.019) and age ≥50 years (OR and 95%CI=3.0 [1.7, 5.4], p=0.0001) were 32 
independently associated with the cholestatic/mixed injury (R≤2). This observation is consistent 33 
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with previous observational studies.[3, 23] Although underlying mechanisms are uncertain, 1 
these findings suggest a gender difference in cholestasis, independent of age and female sex 2 
hormones. The models adjusting for the histologic injury classification showed consistent 3 
associations except for hepatocellular/canalicular cholestasis. Hepatocellular/canalicular 4 
cholestasis could develop in severe hepatocellular injury as a consequence of compromised 5 
cellular energy supply and subsequent impairment of highly energy-dependent transporters 6 
such as BSEP [24], which are difficult to distinguish from true cholestatic injury without 7 
considering overall histologic pictures.   8 
It is well known that women are more prone to develop autoimmune disorders of all types than 9 
are men and that sex hormones significantly modulate innate as well as adaptive immune 10 
responses.[7] Women in general induce stronger antibody-production and cell-mediated 11 
immune responses following either infection or vaccination than men.[7]  Also, there are quite a 12 
few experimental studies showing how estrogens and progesterone influence cellular stress 13 
response and severity of liver injury. Estrogens are in general reported to be protective against 14 
liver injury [25, 26] while progesterone appears to exert detrimental impacts on inflammation 15 
and fibrosis.[27, 28]  Thus, impact of sex and sex hormones on host response to drug toxicity is 16 
likely multilayered [29] and modulates gender-specific clinical phenotypes.   17 
 18 
Another noteworthy finding in our analysis was that black race was associated with about 2-fold 19 
higher likelihood of having more noticeable plasma cell infiltration across the different models 20 
(p-value of 0.048 to 0.08; data are not shown). This is intriguing as black race is reportedly 21 
associated with an enhanced humoral immunological response following vaccination compared 22 
to other races.[30]  A previous study reported that black women were overrepresented among 23 
non-acetaminophen induced acute liver failure.[31, 32] As women were associated with more 24 
noticeable plasma cell infiltration, there may be an additive interaction between gender and 25 
genetic predisposition causing an enhanced humoral immune response in DILI susceptibility 26 
and DILI severity.   27 
A strength of this study is that the analysis was performed using a well-characterized DILI 28 
population with careful follow-up for up to two years in which data were collected and evaluated 29 
in a standardized manner.[14, 33] Also, we applied different modeling approaches to enhance 30 
our data interpretation and theory-generation. This study also has several limitations. We used a 31 
proxy of menopause and the information on exact menopausal state was not available. Possible 32 
misclassification among women may have blunted the true associations. Sex hormone levels 33 
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were not obtained. Our study population may have been biased due to the requirement of liver 1 
biopsy data. Although we evaluated the ‘risk of bias’ and discussed it above, there may be a 2 
bias unmeasured in this study. Therefore, our findings may be applicable only to those who 3 
developed clinically significant drug-induced liver injury and who are likely considered for liver 4 
biopsy. The initiation of liver injury and the type of initial presentation are likely a function of drug 5 
and host and may be determined by their specific interplay.[29]  Host-drug interplay in DILI is 6 
beyond the scope of this analysis. Our analysis was meant to address the impact of gender and 7 
menopause on ‘host response’ to DILI ‘after’ the initiation of injury, but not impact on the 8 
initiation of liver injury or tissue recovery. Host response to drug toxicity is likely modified by 9 
multiple host factors, including concomitant medications and pre-existing co-morbidities,[29] 10 
which were not analyzed in this analysis.  Race/ethnicity, other than Caucasian or black, also 11 
could not be included in this analysis due to their low frequencies. Lastly, our analytic strategy 12 
was built based on our hypothesis. Whether our analytic approach is justifiable from a 13 
mechanistic viewpoint may be questioned. We separately developed a model considering all the 14 
available variables at study enrollment, independent of the hypothesis. This model also 15 
identified gender as a significant contributor in the histologic features analyzed in this study, 16 
which further supports the significance of gender in DILI histology.  17 
In summary, our analysis demonstrated that histologic features of DILI were significantly 18 
associated with gender and age [used as a proxy of menopause] in patients presenting with 19 
varying laboratory profiles. The findings support our hypothesis and generated several 20 
additional intriguing hypotheses relevant to gender differences in injury/stress responses to drug 21 
toxicity (e.g., cell death pathway, inflammation, and immune response). Further clinical analyses 22 
and the translation to experimental studies are warranted to delineate gender-dependent 23 
hepatotoxicity and DILI manifestations.  24 
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Table 1: Clinical Characteristics of the study population 
Clinical characteristics 
Total Women <50 Women >=50 Men 
p-value 
N=212 N=58 N=67 N=87 
Age, year, mean ±SD 50.1 ±15.7 37.1 ± 9.3 62.4 ± 9.0 49.4 ± 15.9 <0.001 
Race 
 
  
 
0.077 
  White, % 77.4 63.8 80.6 83.9 
 
  Black, % 14.6 24.1 11.9 10.3 
 
  Others, % 8.0 12.1 7.5 5.7 
 
Ethnicity Hispanic, % 10.0 15.5 9.1 6.9 0.242 
Biochemical injury type: Hepatocellular injury*, % 50.0 70.7 43.3 41.4 0.002 
Liver chemistries at onset, median(25
th
, 75
th
)      
  ALT, U/L 538 (245, 1268) 770 (267, 1522) 649 (331, 1193) 418 (173, 948) 0.011 
  AST, U/L 353 (137, 989) 738 (224, 1437) 557 (162, 1092) 205 (86, 553) <0.001 
  ALP, U/L 245 (161, 385) 215 (153, 306) 315 (220, 426) 225 (138, 387) <0.001 
  Total bilirubin, mg/dL 7.3 (3.8, 11.9) 5.8 (3.3, 10.4) 6.6 (3.4, 11.9) 8.5 (5.0, 12.9) 0.054 
  INR 1.2 (1.0, 1.5) 1.2 (1.1, 1.6) 1.2 (1.0, 1.7) 1.1 (1.0, 1.3) 0.336 
Positive ANA, % 26.7 30.4 38.8 14.5 0.002 
Time from DILI onset to Liver biopsy, days 9[5, 15] 7[5, 13] 9[5, 15] 9[4, 15] 0.4671 
Primary implicated agents, N ** 
 
  
  Herbs-Dietary Supplements
#
 53 10 11 32 
Amoxicillin/clavulanic acid 26 2 7 17 
 Minocycline 8 4 2 2 
 Nitrofurantoin 6 1 5 0 
 Cefazolin 6 2 3 1 
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Ciprofloxacin 5 1 3 1 
 Levofloxacin 4 1 1 2 
Allopurinol 4 0 2 2  
*: R-value >=5. **: Distributions of implicated drugs (>=4) are provided above. #: Of them, eleven cases were caused by anabolic steroids.  
Table 2: Univariate associations of the gender/age group categories with histologic features  
  
  
Total population Hepatocellular injury  Cholestatic/mixed injury  
F <50 F >=50 Men 
 
F <50 F >=50 Men 
 
F <50 F >=50 Men 
 
N=58 N=67 N=87 N=41 N=29 N=36 N=17 N=38 N=51 
Interface Hepatitis, %    **       *        
  Grade 0 3.6  4.5  10.6   0.0 0.0 11.8   11.8  8.1  9.8   
  Grade 1 19.6  40.9  35.3   12.8 20.7 20.6   35.3  56.8  45.1   
  Grade 2 10.7  16.7  25.9   10.3 13.8 26.5   11.8  18.9  25.5   
  Grade 3 26.8  13.6  14.1   30.8 17.2 11.8   17.6  10.8  15.7   
  Grade 4 39.3  24.2  14.1   46.2 48.3 29.4   23.5  5.4  3.9   
Noticeable plasma cell infiltration, % 37.5   31.8   11.6   ** 41.0   53.6   14.3   * 29.4   15.8   9.8    
Cholestasis, degree, %       **       *       ** 
  Grade 0  48.2   46.3   19.8    53.8   58.6   31.4    35.3   36.8   11.8    
  Grade 1 17.9   16.4   14.0    23.1   24.1   22.9    5.9   10.5   7.8    
  Grade 2 26.8   20.9   27.9    17.9   10.3   34.3    47.1   28.9   23.5    
  Grade 3 7.1   16.4   38.4    5.1   6.9   11.4  11.8   23.7   56.9    
Hepatocellular cholestasis, % 41.1   47.8   72.1   ** 30.8   31.0   57.1   * 64.7   60.5   82.4    
Canalicular cholestasis, % 50.0   52.2   74.4   ** 43.6   41.4   62.9    64.7   60.5   82.4    
Hepatocyte rosettes (more than rare), % 51.8   30.3   17.6   ** 61.5   53.6   38.2    29.4   13.2   3.9   * 
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Lobular disarray present, % 42.9   24.2   15.1   ** 53.8   46.4   34.3    17.6   7.9   2.0   * 
Iron-stain-hepatocytes, %       **       *       ** 
  Grade 0 81.5   63.9   35.9    81.6   65.4   46.7    81.3   62.9   29.2    
  Grade 1 -2 18.5 36.1 64.1  18.4   34.6   53.3    18.8 37.1 70.8  
Apoptosis, %       **               
  Grade 0 10.7   17.9   22.4    5.1   6.9   11.8    23.5   26.3   29.4    
  Grade 1 33.9   47.8   61.2    28.2   31.0   47.1    47.1   60.5   70.6    
  Grade 2 55.4 34.3 16.5   66.7  62.1 41.2    29.4 13.2 0.0    
Lobular inflammation, %              *        
  Grade 0 0.0   0.0   1.2    0.0   0.0   2.9           
  Grade 1 10.7   10.4   11.6    2.6   10.3   11.4    29.4   10.5   11.8    
  Grade 2 5.4   17.9   17.4    2.6   10.3   11.4    11.8   23.7   21.6    
  Grade 3 17.9   25.4   23.3    12.8   6.9   17.1    29.4   39.5   27.5    
  Grade 4 66.1   46.3   46.5    82.1   72.4   57.1    29.4   26.3   39.2    
Lymphoid aggregates/Germinal centers, % 3.6   12.1   4.7    2.6   25.0   8.6   * 5.9   2.6   2.0    
 
  
  
Total population Hepatocellular injury  Cholestatic/mixed injury  
F <50 F >=50 Men 
 
F <50 F >=50 Men 
 
F <50 F >=50 Men 
 
N=58 N=67 N=87 N=41 N=29 N=36 N=17 N=38 N=51 
PAS-positive macrophage, %              *        
  Scattered 13.2   21.7   29.7    5.4   28.0   24.1    31.3   17.1   33.3    
  Clusters 86.8   78.3   70.3    94.6   72.0   75.9    68.8   82.9   66.7    
Lipogranulomas present,% 5.4   21.2   17.4   * 7.7   3.6   8.6    0.0   34.2   23.5   * 
Copper-stained hepatocytes, %                  * 
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  Grade 0  92.6   91.9   82.9    89.7   92.6   93.1    100.0   91.4   76.6    
  Grade 1 7.4   8.1   15.8    10.3   7.4   6.9    0.0   8.6   21.3    
  Grade 2  0.0   0.0   1.3    0.0  0.0 0.0  0.0   0.0   2.1    
Histologic grades were scored in a standardized manner.
16
  * P<0.05, ** P<0.001: for the comparison among gender/age categories (Kruskal-Wallis or Chi-
square test). Eosinophil infiltration, neutrophil infiltration, central vein endophlebitis, nodular transformation, confluent necrosis, hepatocyte ballooning, 
cholangiolar cholestasis, ductular reaction, and sinusoidal reticuloendothelial iron stain were not significantly associated with the gender/age categories in any 
of the above analyses (data not shown).  
 
Table 3a: Associations of the gender/age group categories with histologic features using logistic and ordinal logistic regression models 
Histologic features 
Model 1 Model 2 
Men vs. Women<50(ref) Women>=50 vs. Women<50(ref)  Men vs Women(ref) 
  Odds ratio (95% CI) P value Odds ratio (95% CI) P value Odds ratio (95% CI) P value 
Interface hepatitis
a*
 0.42 (0.22, 0.81) 0.009 0.51 (0.26, 1.02) 0.055 0.63 (0.37, 1.05) 0.076 
Noticeable plasma cell infiltration
b
 0.30 ( 0.13, 0.74) 0.009 1.15 (0.50,  2.50) 0.792 0.29 (0.13,  0.62) 0.002 
Cholestasis degree
b*
 3.63 (1.82, 7.27) <.001 0.94 (0.46, 1.92) 0.868 3.76 (2.15, 6.57) <.001 
Hepatocellular cholestasis
b
 2.85 (1.33,  6.08) 0.007 0.94 (0.43, 2.04) 0.876 2.95 (1.58, 5.48) <.001 
Hepatocyte rosettes
b
 0.29 (0.12, 0.66) 0.004 0.62 (0.27, 1.43) 0.260 0.37 (0.18,  0.76) 0.007 
Canalicular cholestasis
b
  2.36 (1.12, 4.99) 0.025 0.87 (0.41, 1.84) 0.712 2.56 (1.38,  4.73) 0.003 
Lobular disarray
b
 0.36 (0.15, 0.87) 0.023 0.69 (0.29, 1.66) 0.407 0.43 (0.20, 0.94) 0.033 
Iron Satin-hepatocellular iron
b
 8.07 (3.33, 19.53) <.001 2.53 (1.02,  6.28) 0.046 4.53 (2.41,  8.54) <.001 
a
adjusted for liver injury type, black race and age≥70; b adjusted for liver injury type, black race. 
Model 1 was to assess the associations of histologic features in men and women >=50 vs. women <50 (reference) while Model 2 was to assess the associations 
of histologic features in men vs. women (reference). Logistic regression models were used except for the two ordinal variables (*) where proportional odds 
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models were used. For the two ordinal variables, proportional odds assumption was met (score tests). The variable of cholestatsis degree was analyzed with 
three ordinal categories of Grade 0, 1-2, and 3 due to better model fitting. The odds ratio presented is either the usual odds ratio or cumulative odds ratio with 
odds of higher level categories vs. lower level categories. Therefore, an odds ratio of >1 represents an increased likelihood of having a worse outcome. 
Table 3b: Associations of the gender/age group categories with histologic severity of apoptosis using a cumulative logistic regression model 
 
 
Apoptosis 
Model 1 Model 2 
Men vs. Women<50 
COR (95% CI), p value 
Women>=50 vs. Women<50  
COR (95% CI), p value 
Men vs. Women 
COR (95% CI), p value 
Grade 1-2 vs. Grade 0 0.57 (0.19, 1.67),  0.303  0.73 (0.24, 2.20), 0.577  0.70 (0.33, 1.50), 0.359 
Grade 2 vs. Grade 0-1  0.25 (0.11,  0.60),  0.002  0.76 (0.33, 1.76), 0.523  0.29 (0.14, 0.62), 0.001 
Categories of Apoptosis: Grade 0=none to rare, Grade 1= mild, Grade 2= moderate.  COR: cumulative odds ratio. Cumulative logistic 
regression model was fit to the ordinal variable of apoptosis because the proportional odds assumption was not satisfied.  The models were 
adjusted for biochemical injury type and black race with women of <50 as a reference group (Model 1) or women as a reference group 
(Model 2). The cumulative odds ratio was computed as an odds of higher level categories vs. lower level categories, therefore, an odds ratio 
of >1 represents an increased likelihood of having a worse outcome. 
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